Concurrent chemoradiotherapy with weekly nedaplatin versus radiotherapy alone in elderly patients with non-small-cell lung cancer

Chen, F; Hu, P; Liang, N; Xie, J; Yu, S; Tian, T; Zhang, Jingxin; Deng, G; Zhang, Jiandong.
Clin. transl. oncol. (Print) ; 20(3): 294-301, mar. 2018. tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-171316

Documentos relacionados

  1. Concurrent chemoradiotherapy with weekly nedaplatin versus radiotherapy alone in elderly patients with non-small-cell lung cancer.
  2. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
  3. Radical multimodality therapy for malignant pleural mesothelioma.
  4. Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer.
  5. Targeted therapy for rare lung cancers: Status, challenges, and prospects.
  6. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
  7. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.
  8. Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer.
  9. [Immunotherapy and multidisciplinary approach to treatment in lung cancer].
  10. [Chemoradiotherapy Using Molecular Targeted Therapy].